Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Bladder Cancer

Free Subscription 18.05.2026 1 Adv Sci (Weinh) 1 AJR Am J Roentgenol 2 Anal Chem 5 Arch Esp Urol 1 Bioorg Med Chem 3 BJU Int 1 BMJ Case Rep 1 Br J Nurs 1 Cancer Discov 1 Cancer Rep (Hoboken) 1 Cancer Sci 2 Cancers (Basel) 1 Cell Death Differ 1 Cell Rep Med 1 Clin Genitourin Cancer 1 Commun Med (Lond) 1 Cureus 1 Eur Urol 2 Eur Urol Oncol 1 Exp Mol Med 1 Front Bioinform 1 Front Immunol 1 Front Oncol 1 Int J Biol Macromol 2 Int J Mol Sci 2 Int J Surg Pathol 1 Int J Urol 1 Iran J Allergy Asthma Immunol 1 J Cancer Res Clin Oncol 1 J Clin Med 1 J Natl Compr Canc Netw 1 J Transl Med 1 N Biotechnol 1 Oncologist 1 PLoS Biol 1 PLoS One 1 Pract Radiat Oncol 1 Sci Rep 3 Urol Oncol 1 Urology 3 World J Urol

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Adv Sci (Weinh)

1. MA M, Li X, Jing M, Yang Z, et al
   Piezo1 Channel Mediates Mechanically Programmable Drug Delivery to Potentiate Intravesical Chemotherapy.
   Adv Sci (Weinh). 2026;13:e22936.
   PubMed         Abstract available
   
   

   
   AJR Am J Roentgenol

2. DEHGHANPOUR A, Davenport MS, Muglia VF, Nicola R, et al
   Vesical Imaging Reporting and Data System: Overcoming Barriers to Global Implementation-AJR Expert Panel Narrative Review.
   AJR Am J Roentgenol. 2025 Sep 3. doi: 10.2214/AJR.25.33634.
   PubMed         Abstract available
   
   

   
   Anal Chem

3. WANG J, Liu J, Wang Y, Yan W, et al
   Self-Assembled DNA Nanoladder-Based Electrochemical Biosensor for Rapid and Sensitive Detection of Bladder Tumor-Related miRNA in Urine.
   Anal Chem. 2026;98:13845-13853.
   PubMed         Abstract available
   
   
4. ZHANG D, Li M, Yang B, Yan Z, et al
   Plasmon-Enhanced Magnetic Fluorescent Nanoprobe for Ultrasensitive Detection of Urinary miRNA-96 Enabling Early Diagnosis and Risk Stratification of Bladder Cancer.
   Anal Chem. 2026 May 13. doi: 10.1021/acs.analchem.6c01055.
   PubMed         Abstract available
   
   

   
   Arch Esp Urol

5. FENG X, Sun D, Xu L, Zhu C, et al
   Ankaferd versus Immunotherapeutics and Chemotherapeutics in Bladder Cancer.
   Arch Esp Urol. 2026;79:504-512.
   PubMed         Abstract available
   
   
6. TURAN T, Efiloglu O, Hamidzada I, Ahmadzada J, et al
   Predictors of BCG Therapy Complications in Non-Muscle-Invasive Bladder Cancer: A Clavien-Dindo-Based Study.
   Arch Esp Urol. 2026;79:495-503.
   PubMed         Abstract available
   
   
7. WEI F, Zhao M, Sun X, Ma H, et al
   Genetically Predicted Gut Microbiota and Bladder Cancer Risk: A Mendelian Randomisation Analysis.
   Arch Esp Urol. 2026;79:431-439.
   PubMed         Abstract available
   
   
8. NAVARRO-JIMENEZ S, Carrion-Lopez P, Lorenzo-Sanchez MV, Tarraga-Honrubia MA, et al
   Association of Inflammatory and Nutritional Biomarkers with Pathological Response in Patients with Muscle-invasive Bladder Carcinoma Treated with Neoadjuvant Chemotherapy.
   Arch Esp Urol. 2026;79:404-414.
   PubMed         Abstract available
   
   
9. BAUDET LEON J, Cano Velasco J, Polanco Pujol L, Artero Fullana S, et al
   Current Evidence on the Use of Cystoscopy in the Follow-up of Non-Muscle-Invasive Bladder Cancer: Are We Overusing It? Systematic Review of the Literature.
   Arch Esp Urol. 2026;79:362-370.
   PubMed         Abstract available
   
   

   
   Bioorg Med Chem

10. CUI A, Liu H, Wang K, Wei S, et al
    Oleic acid modification enables lysosomal escape of phthalocyanine photosensitizer for effective bladder cancer treatment.
    Bioorg Med Chem. 2026;139:118701.
    PubMed         Abstract available
    
    

    
    BJU Int

11. DIANA P, Di Bello F, Mas L, Gallioli A, et al
    Curriculum-based training improves transurethral resection of bladder tumour performance compared to conventional training: the EuropeaN Training in uRologY (ENTRY) project.
    BJU Int. 2026;137:1026-1031.
    PubMed         Abstract available
    
    
12. CONTIERI R, Martini A, Furrer M, D'Andrea D, et al
    Risk stratification and conditional recurrence after radical cystectomy: toward adaptive follow-up.
    BJU Int. 2026;137:1058-1066.
    PubMed         Abstract available
    
    
13. TILLU N, Wiklund P
    Response to: 'Comment on long-term multicentre analysis of robot-assisted radical cystectomy for non-muscle-invasive bladder cancer'.
    BJU Int. 2026 May 11. doi: 10.1111/bju.70312.
    PubMed        
    
    

    
    BMJ Case Rep

14. SHIVANI ZA, Puthalath RT
    Paraganglioma of the urinary bladder with a novel variant of SDHB mutation.
    BMJ Case Rep. 2026;19:e270375.
    PubMed         Abstract available
    
    

    
    Br J Nurs

15. CHATTERTON K
    Fundamentals of bladder cancer nursing: from diagnosis pathways to holistic care.
    Br J Nurs. 2026;35:S10-S16.
    PubMed         Abstract available
    
    

    
    Cancer Discov

16. YU K, Chen J, Chu YY, Nair S, et al
    A Spatial Atlas of Muscle-Invasive Bladder Cancer Reveals Lineage-Specific Vulnerabilities and Immune Architecture.
    Cancer Discov. 2026 May 13. doi: 10.1158/2159-8290.CD-26-0099.
    PubMed         Abstract available
    
    

    
    Cancer Rep (Hoboken)

17. LIU D, Zhang QY
    Virtual Screening of Traditional Chinese Medicine Natural Product Inhibitors Targeting AQP1 for Bladder Cancer.
    Cancer Rep (Hoboken). 2026;9:e70570.
    PubMed         Abstract available
    
    

    
    Cancer Sci

18. YANG W, Jin Z, Li Z, Xu W, et al
    O-GlcNAcylation of KAT2A Enhances Bladder Cancer Proliferation by Inhibiting the KAT2A-TRIM22 Interaction.
    Cancer Sci. 2026 May 11. doi: 10.1111/cas.70416.
    PubMed         Abstract available
    
    

    
    Cancers (Basel)

19. HOOPER K, McNall S, Pohl D, Sullivan T, et al
    Evidence for a Tumor-Suppressive Role of SHP-1 in EMT Regulation in Bladder Cancer Cells.
    Cancers (Basel). 2026;18:1401.
    PubMed         Abstract available
    
    
20. POPESCU CG, Chipuc S, Zgura D, Haineala B, et al
    Artificial Intelligence-Enhanced Multiparametric MRI and VI-RADS in Bladder Cancer: Current Evidence, Clinical Opportunities and Barriers to Translation.
    Cancers (Basel). 2026;18:1322.
    PubMed         Abstract available
    
    

    
    Cell Death Differ

21. SHIN Y, Kim S, Rhie SK, An W, et al
    HDAC1 has intrinsic protease activity and regulates transcription through clipping histone H3 N-terminal tail.
    Cell Death Differ. 2026;33:1036-1049.
    PubMed         Abstract available
    
    

    
    Cell Rep Med

22. HE Y, Guo H, Wang B, Gao W, et al
    Nectin4-targeted molecular imaging for precise endoscopic diagnosis and image-guided surgery in bladder cancer.
    Cell Rep Med. 2026 May 12:102795. doi: 10.1016/j.xcrm.2026.102795.
    PubMed         Abstract available
    
    

    
    Clin Genitourin Cancer

23. HALME ALE, Posa M, Ruotsalainen J, Hallamies S, et al
    International Survey of Thromboprophylaxis Practices During Neoadjuvant Therapy for Muscle-Invasive Bladder Cancer.
    Clin Genitourin Cancer. 2026 Apr 17:102563. doi: 10.1016/j.clgc.2026.102563.
    PubMed         Abstract available
    
    

    
    Commun Med (Lond)

24. CONROY S, Gagg H, Quayle LA, Adams JA, et al
    Ex vivo drug screening and clustering of bladder cancers for pre-clinical treatment prediction.
    Commun Med (Lond). 2026 May 14. doi: 10.1038/s43856-026-01596.
    PubMed         Abstract available
    
    

    
    Cureus

25. GARG S, Chaurasia JK, Kaushal D, Jayashankar E, et al
    High Immunohistochemical Expression of Runt-Related Transcription Factor 2 (RUNX2) Is Associated With High Tumor Grade, Muscle Invasion, Lymph Node Metastasis, and Advanced Stage in Urinary Bladder Cancer.
    Cureus. 2026;18:e106976.
    PubMed         Abstract available
    
    

    
    Eur Urol

26. BASOURAKOS SP, Shoag J, Calaway A
    Re: Kitamura et al. Active Surveillance Versus Intravesical Bacillus Calmette-Guerin for High-grade T1 Bladder Cancer with Negative Second Transurethral Resection (JCOG1019). Eur Urol 2026. In press. http://dx.doi.org/10.1016/j.eururo.2026.01.008.
    Eur Urol. 2026 May 13:S0302-2838(26)02149-4. doi: 10.1016/j.eururo.2026.
    PubMed        
    
    

    
    Eur Urol Oncol

27. TAN WS, Kamat AM, Lewis R, Porta N, et al
    Outcomes of Intermediate Risk Non-muscle-invasive Bladder Cancer Receiving Adjuvant Treatment: A Pooled Analysis of Four Randomized Controlled Trials.
    Eur Urol Oncol. 2026 May 13:S2588-9311(26)00127.
    PubMed         Abstract available
    
    
28. ZAURITO P, Scilipoti P, Santangelo A, Birtle A, et al
    Neoadjuvant Intravesical Therapy for Patients with Non-muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis.
    Eur Urol Oncol. 2026 May 12:S2588-9311(26)00119.
    PubMed         Abstract available
    
    

    
    Exp Mol Med

29. JEONG J, Jeong G, Kim Y, Ju H, et al
    Machine learning-based integration of transcriptome and digital pathology for predicting chemoresistance in muscle-invasive bladder cancer.
    Exp Mol Med. 2026 May 8. doi: 10.1038/s12276-026-01718.
    PubMed         Abstract available
    
    

    
    Front Bioinform

30. PIZZI JR, Adhikari I, Prakash P, Shi H, et al
    Machine learning-based determination of sex-related bladder cancer biomarkers.
    Front Bioinform. 2026;6:1794098.
    PubMed         Abstract available
    
    

    
    Front Immunol

31. ZOU XC, Xu LY, Yuan YY, Zhang GY, et al
    Disitamab vedotin (RC48) combined with PD-1 inhibitors in locally advanced or metastatic urothelial carcinoma: clinical outcomes and prognostic factors from a multicenter real-world study.
    Front Immunol. 2026;17:1815591.
    PubMed         Abstract available
    
    

    
    Front Oncol

32. ILTZSCHE M, Wetterling N, Jilek L, Nahhas D, et al
    PSCA-directed nanosized bio-immune conjugates (NANO:BICs) enable selective uptake of TLR9 agonists in bladder cancer cells.
    Front Oncol. 2026;16:1739618.
    PubMed         Abstract available
    
    

    
    Int J Biol Macromol

33. WANG K, Hu Z, Zhu Y, Piao C, et al
    LASP1 facilitates bladder cancer progression through binding and downregulating MYH9 to inhibit mitochondrial ROS-induced apoptosis.
    Int J Biol Macromol. 2026;366:152483.
    PubMed         Abstract available
    
    

    
    Int J Mol Sci

34. TARANTINO G, Citro V, Imbimbo C, Crocetto F, et al
    The Insulin-Urothelial Axis: Evaluating Insulin Resistance as a Convergent Driver of Bladder Cancer Across Diverse Risk Factor Profiles.
    Int J Mol Sci. 2026;27:3919.
    PubMed         Abstract available
    
    
35. ALIBEIGINEJAD MH, Esmaielpour A, Tsuboi I, Matsukawa A, et al
    The Prognostic Value of Tumor HER2 Expression in Predicting Oncological Outcomes of Patients with Advanced Urothelial Carcinoma: A Systematic Review and Meta-Analysis.
    Int J Mol Sci. 2026;27:4130.
    PubMed         Abstract available
    
    

    
    Int J Surg Pathol

36. DESHWAL A, Kumar H, Khan A, Parwani A, et al
    Radiation-Induced Epithelioid Angiosarcoma of the Urinary Bladder Mimicking Sarcomatoid Carcinoma: A Rare Entity and Literature Review.
    Int J Surg Pathol. 2026;34:983-989.
    PubMed         Abstract available
    
    
37. NGUYEN TTA, Osunkoya AO
    Endometriosis Involving the Bladder: A Contemporary Clinicopathologic Analysis of 88 Patients.
    Int J Surg Pathol. 2026;34:866-872.
    PubMed         Abstract available
    
    

    
    Int J Urol

38. MATSUYAMA H
    Reviewer's Comment on Skin Phototoxicity With Aminolevulinic Acid Hydrochloride in Patients With Non-Muscle Invasive Bladder Cancer.
    Int J Urol. 2026;33:e70499.
    PubMed        
    
    

    
    Iran J Allergy Asthma Immunol

39. LI Z, Liu C, Wang H
    Exploring the Efficacy of Immunotherapy in Combination with Surgical Resection in High-risk Muscle-invasive Bladder Cancer.
    Iran J Allergy Asthma Immunol. 2026;25:317-329.
    PubMed         Abstract available
    
    

    
    J Cancer Res Clin Oncol

40. JIANG Z, Yuan C, Yuan H, Qin C, et al
    Enhanced detection of bladder cancer using combined circulating tumor cells, urine-derived epithelial cells, and molecular biomarkers.
    J Cancer Res Clin Oncol. 2026 May 10. doi: 10.1007/s00432-026-06469.
    PubMed         Abstract available
    
    

    
    J Clin Med

41. KOSTAKOPOULOS N, Evmorfopoulos K, Maresca G, Athanasiadis G, et al
    Combined Robot-Assisted Radical Cystectomy and Robot-Assisted Nephroureterectomy for Synchronous High-Risk Upper Urinary Tract and Bladder Cancer: A Single-Center Retrospective Study and Review of the Literature.
    J Clin Med. 2026;15:3411.
    PubMed         Abstract available
    
    

    
    J Natl Compr Canc Netw

42. BROWN JR, Parikh M
    Perioperative Systemic Treatment Options for Muscle-Invasive Bladder Cancer.
    J Natl Compr Canc Netw. 2026;24:e267034.
    PubMed         Abstract available
    
    

    
    J Transl Med

43. LOTAN Y, Anai S, Kim H, Gin G, et al
    Detection of bladder cancer in patients with microscopic hematuria using Oncuria-Detect: results of a prospective, multicenter international study.
    J Transl Med. 2026 May 9. doi: 10.1186/s12967-026-08245.
    PubMed         Abstract available
    
    

    
    N Biotechnol

44. YANG M, Li S, Li R, Dong Y, et al
    Organoid-Based Transcriptomics Indicate IFIT-Associated Immune Modulation during Cryptotanshinone Treatment in Bladder Cancer.
    N Biotechnol. 2026 May 13:S1871-6784(26)00060-9. doi: 10.1016/j.nbt.2026.
    PubMed         Abstract available
    
    

    
    Oncologist

45. GUERRERO-RAMOS F, Gomez-Canizo C, Rodriguez-Izquierdo M, Hernandez-Arroyo M, et al
    The combination of atezolizumab and BCG in high-risk non-muscle invasive bladder cancer: results of the phase Ib/II BladderGATE clinical trial.
    Oncologist. 2026 May 8:oyag177. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    PLoS Biol

46. ZHANG J, Huang L, Wang S, Ding J, et al
    Acoustic delivery of indocyanine green via biosynthetic gas vesicles for tumor photothermal therapy.
    PLoS Biol. 2026;24:e3003786.
    PubMed         Abstract available
    
    

    
    PLoS One

47. 
    Retraction: Does Occupational Exposure to Solvents and Pesticides in Association with Glutathione S-Transferase A1, M1, P1, and T1 Polymorphisms Increase the Risk of Bladder Cancer? The Belgrade Case-Control Study.
    PLoS One. 2026;21:e0349169.
    PubMed        
    
    

    
    Pract Radiat Oncol

48. CHENG T, Hao H, Liu C, Li X, et al
    Mapping Patterns of Pelvic Lymph Node Metastasis in Bladder Urothelial Carcinoma: Implications for Personalized Pelvic Radiation Therapy.
    Pract Radiat Oncol. 2026;16:e210-e218.
    PubMed         Abstract available
    
    

    
    Sci Rep

49. PATIL B, Hadjiiski L, Sun D, Chan HP, et al
    Bladder cancer segmentation using u-net-based deep-learning.
    Sci Rep. 2026 May 13. doi: 10.1038/s41598-026-52716.
    PubMed         Abstract available
    
    

    
    Urol Oncol

50. NOEL ODV, Akgul B, Bhandari M, Ramos F, et al
    Clinical trial participation in kidney, bladder, and prostate malignancies in the United States: Sociodemographic distribution and impact on survival.
    Urol Oncol. 2026;44:176-188.
    PubMed         Abstract available
    
    
51. GHOREIFI A, Hoimes CJ, Ramalingam S, McManus HD, et al
    Outcomes of consolidative surgery following enfortumab vedotin plus pembrolizumab for advanced urothelial cancer: A real-world experience.
    Urol Oncol. 2026;44:80-85.
    PubMed         Abstract available
    
    
52. NASRALLAH AA, Evans C, Gu L, Parrish JA, et al
    Costs of care and oncologic outcomes associated with blue light cystoscopy in an equal access setting: Results from the BRAVO study.
    Urol Oncol. 2026;44:70-79.
    PubMed         Abstract available
    
    

    
    Urology

53. SRIDALLA K, Nicolas JD, Zhao L, French DD, et al
    Contemporary Microhematuria Evaluation in Veterans: Cancer Detection and Resource Utilization.
    Urology. 2026;211:29-34.
    PubMed         Abstract available
    
    

    
    World J Urol

54. VENTURA Y, Morozov A, Chan R, Combat Faria Tavares M, et al
    Pathological assessment of morcellated tissue after ERBT: insights from a two-round Delphi survey.
    World J Urol. 2026;44:351.
    PubMed         Abstract available
    
    
55. COURNEDE M, Gabriel PE, Lottin M, Moschini M, et al
    Multi-institutional external validation of the European risk classification for high-grade Ta non-muscle-invasive bladder cancer.
    World J Urol. 2026;44:358.
    PubMed         Abstract available
    
    
56. LAFITTE E, Sfumato P, Walz J, Billon E, et al
    Chemotherapy-induced anemia as a prognostic factor for overall survival in patients with bladder cancer treated with neoadjuvant cisplatin-based chemotherapy and cystectomy.
    World J Urol. 2026;44:364.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum